

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization  
International Bureau(43) International Publication Date  
30 March 2006 (30.03.2006)

PCT

(10) International Publication Number  
WO 2006/033641 A1(51) International Patent Classification<sup>7</sup>: A61F 2/06(21) International Application Number:  
PCT/SG2004/000425(22) International Filing Date:  
22 December 2004 (22.12.2004)

(25) Filing Language: English

(26) Publication Language: English

(71) Applicant (for all designated States except US): MERLIN  
MD PTE LTD [SG/SG]; 29 Woodlands Industrial Park E1,  
#04-13/14 Northtech (Lobby 3), Singapore 757716 (SG).

(72) Inventors; and

(75) Inventors/Applicants (for US only): RUDAKOV, Leon  
[US/US]; 22 Arroyo View Circle, Belmont, CA 94002  
(US). HONG, Tsui Ying, Rachel [MY/SG]; Block 603,  
Senja Road #12-61, Singapore 670603 (SG).(74) Agent: ALBAN TAY MAHTANI & DE SILVA; 39  
Robinson Road, #07-01 Robinson Point, Singapore  
068911 (SG).(81) Designated States (unless otherwise indicated, for every  
kind of national protection available): AE, AG, AL, AM,  
AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN,CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI,  
GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE,  
KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD,  
MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG,  
PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY,  
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU,  
ZA, ZM, ZW.(84) Designated States (unless otherwise indicated, for every  
kind of regional protection available): ARIPO (BW, GH,  
GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM,  
ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),  
European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI,  
FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO,  
SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,  
GQ, GW, ML, MR, NE, SN, TD, TG).

## Declaration under Rule 4.17:


— of inventorship (Rule 4.17(iv)) for US only

## Published:

- with international search report
- before the expiration of the time limit for amending the  
claims and to be republished in the event of receipt of  
amendments
- upon request of the applicant, before the expiration of the  
time limit referred to in Article 21(2)(a)

[Continued on next page]

(54) Title: A MEDICAL DEVICE



(57) Abstract: A medical device (10) for insertion into a bodily vessel (6) to treat an aneurysm (5) having an aneurysm neck, the device (10) comprising: a mechanically expandable device (20) expandable from a first position to a second position, said mechanically expandable device (20) is expanded radially outwardly to the second position such that the exterior surface of said mechanically expandable device (20) engages with the inner surface of the vessel (6) so as to maintain a fluid pathway through said vessel (6); a therapeutically effective amount of a chemical compound comprising a biosynthesis accelerator to stimulate cell growth; and a polymer (30, 41, 42) mixed with the chemical compound to manage the release rate of the chemical compound; wherein the mechanically expandable device (20) provides a support for the release of the chemical compound within the aneurysm (5) to stimulate cell growth within the aneurysm (5) and close the aneurysm neck.



---

*For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

**Title****A Medical Device****Technical Field**

- 5 The invention concerns a medical device for insertion into a bodily vessel to treat an aneurysm having an aneurysm neck.

**Background of the Invention**

- 10 Intracranial aneurysms are currently treated by engaging neurosurgical clipping or using several minimally invasive techniques. For example, interventional neuroradiology uses minimally invasive methods to treat aneurysms. Other methods include: coiling, stenting and coiling; and using gels, glues, or fibrin sealants.

15

There is a desire to treat aneurysms such that it does not leave any mass (such as solid coils) or foreign body material in a healed aneurysm.

**Summary of the Invention**

20

In a first preferred aspect, there is provided a medical device for insertion into a bodily vessel to treat an aneurysm having an aneurysm neck, the device comprising:

- 25 a mechanically expandable device expandable from a first position to a second position, said mechanically expandable device is expanded radially outwardly to the second position such that the exterior surface of said mechanically expandable device engages with the inner surface of the vessel so as to maintain a fluid pathway through said vessel;

- 30 a therapeutically effective amount of a chemical compound comprising a biosynthesis accelerator to stimulate cell growth; and

a polymer mixed with the chemical compound to manage the release rate of the chemical compound;

- 35 wherein the mechanically expandable device provides a support for the release of the chemical compound within the aneurysm to stimulate cell growth within the aneurysm and close the aneurysm neck.

The accelerator may be a threo-1-phenyl-2-decanoylamino-3-morpholino-1-propanol compound. Specifically, the accelerator may be L-threo-1-phenyl-2-decanoylamino-3-morpholino-1-propanol (L-PDMP) and therapeutically acceptable salts thereof.

Synthetic ceramide analog, L-PDMP, may stimulate the biosynthesis of glycosphingolipids (GSL) such as Lactosylceramide (LacCer) and glucosylceramide (GlcCer), which in turn stimulates cell growth.

The polymer may be biocompatible, biodegradable, hydrophilic, and has a high degree of swelling.

The polymer may be in a solid or highly viscous form, or is highly elastic.

The polymer may comprise a hydrophilic shell and a hydrophobic core or solely consists of a hydrophilic composition.

The polymer may be selected from the group consisting of: synthetic biodegradable polymers such as Poly (glycolic acid) (PGA), Poly (lactic acid) (PLA), Poly (lactic-co-glycolic acid) (PLGA), poly (ε-caprolactone), Polyanhydride, poly (orthoesters), polyphosphazane; biodegradable polymers from natural sources such as modified polysaccharides (cellulose, chitin, dextran) and Modified proteins (fibrin, casein); and hydrogels or superabsorbants such as Poly (ethylene oxide) (PEO), Poly (ethylene glycol) PEG, Methylacrylate (MAA), Maleic anhydride (MAH), Polyacrylamide, Poly (hydroxyethyl methacrylate), Poly (N-vinyl pyrrolidone), Poly (vinyl alcohol).

The L-PDMP compound may be coated on 2D or 3D platinum coils.

The mechanically expandable device may comprise a generally tubular structure having an exterior surface defined by a plurality of interconnected struts having interstitial spaces therebetween.

The polymer and chemical compound may be released into the aneurysm by a delivery catheter passing through the mechanically expandable device and between the struts of the mechanically expandable device proximal to the aneurysm.

The polymer and chemical compound may be in the form of micro-spheres, spherical, or cylindrical (with coils).

5 The delivery catheter may comprise a distal compartment for securing the chemical compound, and a proximal compartment, the distal and proximal compartments being separated by an elastic membrane, wherein pressure applied to the proximal compartment is translated to the distal compartment causing the polymer and chemical compound to be released from the delivery catheter into the aneurysm.

10 The delivery catheter may further comprise a valve to allow exit of the polymer and chemical compound but prevents blood from entering the delivery catheter.

15 The polymer and the chemical compound may be in the form of a membrane attached to the outer surface of the mechanically expandable device, such that when the mechanically expandable device is expanded, the membrane faces the aneurysm and the chemical compound is released towards the aneurysm.

The membrane may be a single layer or comprises multiple layers.

The membrane may be biodegradable.

20

The polymer may be solid or porous.

The polymer may be amorphous or semi-crystalline.

25 The device may further comprise radiopaque markers incorporated in the polymer to improve the visibility of the polymer and chemical compound during deployment.

The device may further comprise radiopacifiers such as barium sulphate, zirconium dioxide or iodine.

30 The mechanically expandable device may be biodegradable.  
The mechanically expandable device and polymer may biodegrade at different rates.

35 In a second aspect, there is provided a method for treating an aneurysm having an aneurysm neck, the method comprising:

positioning a mechanically expandable device into a bodily vessel proximate to the aneurysm neck;

releasing a therapeutically effective amount of a chemical compound comprising a biosynthesis accelerator to stimulate cell growth within the aneurysm;

wherein the mechanically expandable device provides a support for the release of the chemical compound within the aneurysm to stimulate cell growth within the aneurysm and close the aneurysm neck.

The method may further comprise passing a delivery catheter through the mechanically expandable device and between the struts of the mechanically expandable device proximal to the aneurysm, to deliver the chemical compound.

The method may further comprise mechanically pushing the chemical compound from the delivery catheter and into the aneurysm.

The method may further comprise applying pressure in a proximal compartment of the delivery catheter to cause the chemical compound to be pushed out of a distal compartment of the delivery catheter and into the aneurysm.

#### Brief Description of the Drawings

An example of the invention will now be described with reference to the accompanying drawings, in which:

Figure 1 is an illustration of the molecular structure of Poly (glycolic acid);

Figure 2 is an illustration of the molecular structure of Poly (lactic acid);

Figure 3 is an illustration of the molecular structure of Poly (lactic-co-glycolic acid);

Figure 4 is a diagrammatic view of a delivery catheter delivering the polymer and L-PDMP compound;

Figure 5 is a diagrammatic view of the polymer in two forms;

Figure 6 is a diagrammatic view of the polymer in membrane form;

Figure 7 is an illustration of the molecular structure of L-PDMP;

Figure 8 is a diagrammatic view of a stent positioned across an aneurysm;

Figure 9 is a diagrammatic view of the delivery catheter delivering the polymer and L-PDMP compound into the aneurysm;

Figure 10 is a diagrammatic view of the polymer and L-PDMP compound filling the aneurysm and embolising;

Figure 11 is a diagrammatic view of a membrane attached to the stent for releasing the L-PDMP compound into the aneurysm;

Figure 12 is a diagrammatic view of the L-PDMP compound degrading and the aneurysm healing; and

Figure 13 is a diagrammatic view of the membrane biodegrading and the aneurysm healing.

5

#### Detailed Description of the Drawings

Referring to the drawings, the medical device generally comprises three components: a stent 20, a polymer 30, 41, 42 and L-threo-1-Phenyl-2-Decanoylamino-3-Morpholino-1-Propanol (L-PDMP) compound. A first embodiment of the medical device comprises the stent 20 and a biodegradable, hydrophilic polymer 30 mixed with the L-PDMP compound. A second embodiment of the medical device comprises the stent 20 with a biodegradable membrane 41, 42 with at least one layer of the hydrophilic polymer 30.

15

The stent 20 may be made of the following materials utilizing different deployment mechanisms:

- Balloon expandable stent made from: stainless steel, PtW alloy, or Ti;
- Self-expandable stent made from NiTi; or
- 20 • Biodegradable stent.

If the stent 20 is deployed by balloon expansion, it is made from stainless steel, platinum tungsten alloy or titanium. If the stent 20 is deployed by self expansion, it is made from Nitinol.

25

Suitable biodegradable materials for the stent 20 include:

- Poly (glycolic acid) (PGA) as shown in Figure 1;
- Poly (lactic acid) (PLA) as shown in Figure 2;
- Poly (lactic-co-glycolic acid) (PLGA) as shown in Figure 3;
- 30 • Poly (ecaprolactone) (PCL);
- Polyanhydride (PA); or
- Poly (orthoesters) (POE).

If the stent 20 is made from a biodegradable material, foreign material in the vessel  
35 6 is reduced or eliminated after the aneurysm 5 is healed. The stent 20 also biodegrades while the aneurysm 5 is healing.

Referring to Figures 4, 5 and 6, the polymer 30, 41, 42 is a medium for the attaching the L-PDMP compound. The polymer 30, 41, 42 manages the release rate of the L-PDMP compound and also provides a scaffold for cell growth. The shape of the polymer 30, 41, 42 may include: micro-spheres 30, spherical 30, cylindrical (with coils), or be in the form of a thin membrane 41, 42.

The polymer 30 is biocompatible, biodegradable, hydrophilic, has a high degree of swelling. The polymer 30 has a fast swelling rate (from instantaneous to approximately 5 to 6 minutes). The polymer 30 may be in a solid or highly viscous form, or is highly elastic.

The polymer 30 is based on any one of the following materials:

- Synthetic biodegradable polymer such as Poly (glycolic acid) (PGA), Poly (lactic acid) (PLA), Poly (lactic-co-glycolic acid) (PLGA), poly (ecaprolactone), Polyanhydride, poly (orthoesters), polyphosphazane;
- Biodegradable polymers from natural sources such as modified polysaccharides (cellulose, chitin, dextran) and Modified proteins (fibrin, casein); and
- Hydrogels or superabsorbants such as Poly (ethylene oxide) (PEO), Poly (ethylene glycol) PEG, Methacrylate (MAA), Maleic anhydride (MAH), Polyacrylamide, Poly (hydroxyethyl methacrylate), Poly (N-vinyl pyrrolidone), Poly (vinyl alcohol).

Referring to Figure 7, L-PDMP is a chemical compound which promotes a glycolipid biosynthesis-accelerating effect. This is described in US Patent 5,041,441 and Japanese Patent 254623/1989. L-PDMP or its derivatives are used to enhance healing and facilitate closing of the aneurysm 5. L-PDMP is used with other types of enzyme GalT-2 enhancing compounds (including L-PDMP and its derivatives) for the purpose of cell proliferation, including targeting cells such as endothelial, smooth muscle and other types of cells that are available in the intracranial vascular system. Cell proliferation embolizes and effectively obstructs blood circulation to the aneurysm 5. Also, the aneurysm 5 is naturally healed because the aneurysm 5 is deprived of blood circulation and nutrient supply.

The L-PDMP compound is locally released within the aneurysm 5. The release profile of the L-PDMP compound has an initial burst release within the first few



hours, to activate biosynthesis and form an outer sphere of emboli, thus enhancing the process of closing the aneurysm neck 5 with a biological cell based substrate. This is followed by a steady state release lasting for 1 to 2 weeks. The L-PDMP compound is designed to activate biosynthesis after it is released. The L-PDMP compound stimulates the biosynthesis of glycosphingolipids (GSL), specifically Lactosylceramide (LacCer) and glucosylceramide (GlcCer). GSLs exist as constitutional component of cell surface membranes and are closely related to a cellular function. GlcCer is precursors for other complex GSLs and are involved in proliferation of cells. LacCer is present in vascular cells such as smooth muscle cells, endothelial cells, macrophages, neutrophils, platelets and monocytes, all of which are involved in the natural healing process. It also serves as a lipid second messenger that orchestrates a signal transduction pathway, leading to cell proliferation.

- 15 The acceleration of GSL biosynthesis leads to the following cellular response:
- fibroblast and endothelial cell growth;
  - promotion of collagen formation and smooth muscle cell proliferation; and
  - occlusion of the aneurysm and neointima coverage of the aneurysm neck. The aneurysm is removed from normal blood circulation.

20 The healing process begins when the aneurysm neck 5 is filled by the proliferation of cells activated by the L-PDMP compound. The membrane 30, 41, 42 and stent 20 biodegrade over time.

25 **Example 1**

In the first embodiment, the medical device includes a stent 20 with a biodegradable hydrophilic viscous composition 30, that is, a highly viscous solution of biodegradable, hydrophilic material mixed with the L-PDMP compound. In a specific example, the L-PDMP compound is coated on 2D or 3D platinum coils.

30 Alternatively, one coil is used in parallel with gel spheres used as markers.

The stent 20 assists with the delivery of the L-PDMP compound to a selected aneurysm site 5 by supporting or scaffolding the vessel 6 and protecting and securing the L-PDMP composition introduced into the aneurysm 5. A delivery catheter 40 is provided to deploy the L-PDMP compound in a controlled manner to treat the aneurysm 5. After the stent 20 is positioned at a selected aneurysm site 5, the L-PDMP compound is deployed using the delivery catheter 40 to create an

embolization environment at the aneurysm site 5. This eventually causes the aneurysm neck 5 to close as a result of the biological reaction caused by L-PDMP compound and subsequent biological activity.

- 5 The polymer 30 is delivered as a single particle or as connected smaller particles. The microstructure of the polymer 30 may be solid or porous (micropores (10-100nm), macropores (100nm-10 $\mu$ m) or superpores ( $\approx$ 100 $\mu$ m). The polymer 30 is either amorphous or semi-crystalline. If radiopaque markers are used, platinum coils are incorporated in the polymer 41, 42. Radiopacifiers are added to the  
10 polymer 41, 42 such as barium sulphate (BaSO<sub>4</sub>), zirconium dioxide (ZrO<sub>2</sub>) and iodine.

- Referring to Figure 5a, the particle(s) 30 facilitate the rate and degree of swelling as well as the rate of degradation. These particles 30 consist entirely of a  
15 hydrophilic polymer, for fast release and degradation. Alternatively, referring to Figure 5b, the particle(s) 30 consists of an outer shell of a hydrophilic polymer with a core made of hydrophobic polymer, such as polyanhydride, poly (ortho esters) or poly (L-lactic acid), for greater sustained release and extend degradation time if needed.

- 20 Referring to Figure 8, the stent 20 is deployed and expanded against the aneurysm neck 5 to create a scaffold or support. The polymer 30 and L-PDMP compound is secured in a distal compartment at the distal tip of the delivery catheter 40. Next, the delivery catheter 40 with the hydrophilic substrate is introduced to the  
25 aneurysm 5. The hydrophilic substrate is a mixture of hydrophilic viscous biodegradable material with L-PDMP compound.

- Referring to Figure 9, the distal tip of the delivery catheter 40 is introduced to the aneurysm neck 5 between the stent struts. When the distal tip is positioned in or  
30 near the aneurysm neck 5, the polymer 30 and L-PDMP compound is released from the distal compartment by mechanically pushing the L-PDMP compound with a core wire in the inner lumen of the delivery catheter 40. The tip of the delivery catheter 40 has a valve to allow the L-PDMP compound to exit but prevents blood from entering to reduce premature swelling of the polymer 30 and activation of the  
35 L-PDMP. The L-PDMP compound is pushed out of the inner lumen of the delivery catheter 40 by a core wire. The core wire functions similarly to a piston in a hydraulic cylinder.

Another way to deploy the L-PDMP compound is to modify the delivery catheter 40 by providing an inner lumen proximal/mid-shaft compartment and distal compartment within the delivery catheter 40. The L-PDMP compound is secured within the distal compartment. The proximal and distal compartments of the delivery catheter 40 are separated by a super elastic membrane. When pressure is applied to the proximal compartment, the membrane transfers the pressure from proximal compartment to the distal compartment and thus pushes the L-PDMP compound out of the delivery catheter 40 and into the aneurysm 5.

Referring to Figure 10, upon release, the polymer 30 and L-PDMP compound immediately absorbs the blood within the aneurysm 5 and swells to a size larger than the stent struts, at a fixed rate. The inner space of the aneurysm 5 is filled up after deployment is completed and the L-PDMP compound is released and activated. A biological cell based substrate is formed and swells and expands. It grows in size very quickly size, larger than the distance between stent struts. At this point, the stent struts prevent the substrate from returning towards the vessel. After the substrate occupies the aneurysm dome 5, it starts releasing the L-compound and activating the cell proliferation and embolization process. The L-PDMP compound is designed to be active only during its release and facilitates the embolization process as long as it needed. The L-PDMP compound ceases activity after its release is seized. After the aneurysm dome 5 is filled by newly developed emboli, blood supply into the aneurysm 5 is reduced and eventually stopped. The biodegradable material gradually biodegrades leaving the healing site with a natural vessel wall.

### **Example 2**

In the second embodiment, the medical device includes a stent 20 with a biodegradable membrane 41, 42 made from biodegradable material mixed with the L-PDMP compound. The stent 20 is deployed at the aneurysm site 5 against its neck. The membrane 41, 42 obstructs blood circulation through the aneurysm neck to the aneurysm 5. The L-PDMP compound is encased in layers of the membrane 42. The L-PDMP compound starts to release and activate cell proliferation towards the aneurysm neck and dome 5.

35

The membrane 41, 42 is made from a mixture of the biodegradable polymer and L-PDMP compound. The direction that the L-PDMP compound is released is controlled and directed outwards towards the vessel wall and aneurysm neck.

- 5 Referring to Figure 6a and 6b, if the polymer is in the form of a membrane 41, 42 to cover the aneurysm 5, the polymer is a single layer of biodegradable polymer 41 or is multi-layered 42; consisting of both biodegradable materials. The microstructure of the polymer 41, 42 may be solid or porous (micropores (10-100nm), macropores (100nm-10 $\mu$ m) or superpores ( $\approx$ 100 $\mu$ m). The polymer 41, 42 is either amorphous  
10 or semi-crystalline. If radiopaque markers are used, platinum coils are incorporated in the polymer 41, 42. Radiopacifiers are added to the polymer 41, 42 such as barium sulphate (BaSO<sub>4</sub>), zirconium dioxide (ZrO<sub>2</sub>) and iodine.

- Referring to Figure 11, a thin film membrane 41 is made of a biodegradable  
15 polymer and the L-PDMP compound. The membrane 41 is attached to stent struts. Alternatively, a non-biodegradable polymer can be used. When the stent 20 is deployed, the membrane 41 obstructs blood circulation through the neck of the aneurysm 5. The L-PDMP compound is activated and released towards the aneurysm neck and dome 5.

- 20 Referring to Figures 12 and 13, the polymer 30, 41, 42 slowly degrades after deployment. The degradation/release time varies from 10 to 14 days to 1 to 2 months. The degradation is controllable by mechanisms and structures described. This enables the aneurysm to 5 heal completely, and leaves a natural vessel wall  
25 6.

- The medical device is suitable for different aneurysm sizes, including small aneurysms (<15mm), large aneurysms (15-25mm), giant aneurysms (25-50mm) as well as different aneurysm types such as Berry aneurysm or wide neck aneurysm  
30 (neck >4mm and/or dome-to-neck ratio <2).

- It will be appreciated by persons skilled in the art that numerous variations and/or modifications may be made to the invention as shown in the specific embodiments without departing from the scope or spirit of the invention as broadly described.  
35 The present embodiments are, therefore, to be considered in all respects illustrative and not restrictive.

**WE CLAIM:**

1. A medical device for insertion into a bodily vessel to treat an aneurysm having an aneurysm neck, the device comprising:
  - 5 a mechanically expandable device expandable from a first position to a second position, said mechanically expandable device is expanded radially outwardly to the second position such that the exterior surface of said mechanically expandable device engages with the inner surface of the vessel so as to maintain a fluid pathway through said vessel;
  - 10 a therapeutically effective amount of a chemical compound comprising a biosynthesis accelerator to stimulate cell growth; and  
a polymer mixed with the chemical compound to manage the release rate of the chemical compound;  
wherein the mechanically expandable device provides a support for the  
15 release of the chemical compound within the aneurysm to stimulate cell growth within the aneurysm and close the aneurysm neck.
2. The device according to claim 1, wherein the accelerator is a threo-1-phenyl-2-decanoylamino-3-morpholino-1-propanol compound.  
20
3. The device according to claim 2, wherein the accelerator is L-threo-1-phenyl-2-decanoylamino-3-morpholino-1-propanol (L-PDMP) and therapeutically acceptable salts thereof.
- 25 4. The device according to claim 3, wherein the L-PDMP compound stimulates the biosynthesis of glycosphingolipids (GSL)
5. The device according to claim 4, wherein the L-PDMP compound stimulates the biosynthesis of Lactosylceramide (LacCer) and glucosylceramide  
30 (GlcCer).
6. The device according to claim 1, wherein the polymer is biocompatible, biodegradable, hydrophilic, and has a high degree of swelling.
- 35 7. The device according to claim 6, wherein the polymer is in a solid or highly viscous form, or is highly elastic.

8. The device according to 1, wherein the polymer comprises a hydrophilic shell and a hydrophobic core or solely consists of a hydrophilic composition.

9. The device according to claim 1, wherein the polymer is selected from the group consisting of: synthetic biodegradable polymers such as Poly (glycolic acid) (PGA), Poly (lactic acid) (PLA), Poly (lactic-co-glycolic acid) (PLGA), poly (ecaprolactone), Polyanhydride, poly (orthoesters), polyphosphazane; biodegradable polymers from natural sources such as modified polysaccharides (cellulose, chitin, dextran) and Modified proteins (fibrin, casein); and hydrogels or superabsorbants such as Poly (ethylene oxide) (PEO), Poly (ethylene glycol) PEG, Methylacrylate (MAA), Maleic anhydride (MAH), Polyacrylamide, Poly (hydroxyethyl methacrylate), Poly (N-vinyl pyrrolidone), Poly (vinyl alcohol).

10. The device according to claim 3, wherein the L-PDMP compound is coated on 2D or 3D platinum coils.

11. The device according to claim 1, wherein the mechanically expandable device comprises a generally tubular structure having an exterior surface defined by a plurality of interconnected struts having interstitial spaces therebetween.

20

12. The device according to claim 11, wherein the polymer and the chemical compound are released into the aneurysm by a delivery catheter passing through the mechanically expandable device and between the struts of the mechanically expandable device proximal to the aneurysm.

25

13. The device according to claim 12, wherein the polymer and the chemical compound are in the form of micro-spheres, spherical, or cylindrical (with coils).

14. The device according to claim 12, wherein the delivery catheter comprises a distal compartment for securing the polymer and the chemical compound, and a proximal compartment, the distal and proximal compartments being separated by an elastic membrane, wherein pressure applied to the proximal compartment is translated to the distal compartment causing the polymer and the chemical compound to be released from the delivery catheter into the aneurysm.

35

15. The device according to claim 14, wherein the delivery catheter further comprises a valve to allow exit of the polymer and the chemical compound but prevents blood from entering the delivery catheter.
- 5 16. The device according to claim 1, wherein the polymer and the chemical compound are in the form of a membrane attached to the outer surface of the mechanically expandable device, such that when the mechanically expandable device is expanded, the membrane faces the aneurysm and the chemical compound is released towards the aneurysm.
- 10 17. The device according to claim 16, wherein the membrane is a single layer or comprises multiple layers.
18. The device according to claim 16, wherein the membrane is  
15 biodegradable.
19. The device according to claim 16, wherein the polymer is solid or porous.
20. The device according to claim 16, wherein the polymer is amorphous or  
20 semi-crystalline.
21. The device according to claim 1, further comprising radiopaque markers incorporated in the polymer to improve the visibility of the polymer and chemical compound during deployment.
- 25 22. The device according to claim 21, further comprising radiopacifiers such as barium sulphate, zirconium dioxide or iodine.
23. The device according to claim 1, wherein the mechanically expandable  
30 device is biodegradable.
24. The device according to claim 23, wherein the mechanically expandable device and polymer biodegrade at different rates.
- 35 25. A method for treating an aneurysm having an aneurysm neck, the method comprising:

positioning a mechanically expandable device into a bodily vessel proximate to the aneurysm neck;

releasing a therapeutically effective amount of a chemical compound comprising a biosynthesis accelerator to stimulate cell growth within the aneurysm;

- 5        wherein the mechanically expandable device provides a support for the release of the chemical compound within the aneurysm to stimulate cell growth within the aneurysm and close the aneurysm neck.

26.        The method according to claim 25, further comprising passing a delivery  
10        catheter through the mechanically expandable device and between the struts of the mechanically expandable device proximal to the aneurysm, to deliver the chemical compound.

27.        The method according to claim 26, further comprising mechanically  
15        pushing the chemical compound from the delivery catheter and into the aneurysm.

28.        The method according to claim 26, further comprising applying pressure in  
a proximal compartment of the delivery catheter to cause the chemical compound  
to be pushed out of a distal compartment of the delivery catheter and into the  
20        aneurysm.






Figure 1: Molecular structure of Poly (glycolic acid)




Figure 2: Molecular structure of Poly (lactic acid)





Figure 3: Molecular structure of Poly (lactic-co-glycolic acid)

FIGURE 4







Figure 5: Polymer consists of a) entirely of hydrophilic polymer and b) an outer hydrophilic shell and hydrophobic core



a) b)  
Figure 6: Polymer for patch made from a) a single layer of hydrophilic material and b) multi-layer, with hydrophilic and hydrophobic polymers




Figure 7: Molecular structure of L-PDMP




Figure 8: Stent deployed across aneurysm




Figure 9: Position of Delivery catheter




Figure 10: Polymer and L-PDMP composition filling aneurysm and embolises






Figure 11: Patch covering aneurysm neck




Figure 12: Healed aneurysm




Figure 13: Healed aneurysm

## INTERNATIONAL SEARCH REPORT

International application No.  
PCT/SG2004/000425

<b>A. CLASSIFICATION OF SUBJECT MATTER</b> Int. Cl. <sup>7</sup> : A61F 2/06 According to International Patent Classification (IPC) or to both national classification and IPC					
<b>B. FIELDS SEARCHED</b> Minimum documentation searched (classification system followed by classification symbols) Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched Electronic data base consulted during the international search (name of data base and, where practicable, search terms used) DWPI IPC A61F, A61M, A61B, A61K, A61P and Keywords (aneurysm, stent, cell, accelerator) and like terms MEDLINE Keywords (stent, aneurysm, PDMP, L-threo-1-phenyl-2-decanoylamino-3-morpholino-1-propanol) and like terms					
<b>C. DOCUMENTS CONSIDERED TO BE RELEVANT</b>					
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.			
Y	EP 1470795 A1 (MEDTRONIC VASCULAR INC) 27 October 2004 Whole document	1-28			
Y	US 2004/0170685 A1 (CARPENTER et al) 2 September 2004 Whole document	1-28			
Y	WO 2004/000379 A1 (ADVANCED CARDIOVASCULAR SYSTEMS INC) 31 December 2003 Whole document	1-28			
<input checked="" type="checkbox"/> Further documents are listed in the continuation of Box C <input checked="" type="checkbox"/> See patent family annex					
<table style="width: 100%; border: none;"> <tr> <td style="width: 33%; vertical-align: top;">           * Special categories of cited documents:            "A" document defining the general state of the art which is not considered to be of particular relevance            "E" earlier application or patent but published on or after the international filing date            "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)            "O" document referring to an oral disclosure, use, exhibition or other means            "P" document published prior to the international filing date but later than the priority date claimed         </td> <td style="width: 33%; vertical-align: top;">           "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention            "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone            "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art            "&amp;" document member of the same patent family         </td> <td style="width: 33%;"></td> </tr> </table>			* Special categories of cited documents: "A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier application or patent but published on or after the international filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed	"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art "&" document member of the same patent family	
* Special categories of cited documents: "A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier application or patent but published on or after the international filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed	"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art "&" document member of the same patent family				
Date of the actual completion of the international search 9 February 2005		Date of mailing of the international search report 15 FEB 2005			
Name and mailing address of the ISA/AU AUSTRALIAN PATENT OFFICE PO BOX 200, WODEN ACT 2606, AUSTRALIA E-mail address: pct@ipaaustralia.gov.au Facsimile No. (02) 6285 3929		Authorized officer  SUE THOMAS Telephone No : (02) 6283 2454			

## INTERNATIONAL SEARCH REPORT

International application No.

PCT/SG2004/000425

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	US 2002/0065546 A1 (MACHAN et al) 30 May 2002 Whole document	1-28
Y	WO 2001/003607 A2 (SCIMED LIFE SYSTEMS INC) 18 January 2001 Whole document	1-28
Y	WO 1999/062432 A1 (NEW YORK UNIVERSITY et al) 9 December 1999 Whole document	1-28
Y	WO 1999/002092 A1 (SCIMED LIFE SYSTEMS INC) 21 January 1999 Whole document	1-28
Y	CHATTERJEE, S "Lactosylceramide stimulates aortic smooth muscle cell proliferation" Biochemical and Biophysical Research Communications, Vol.181 No.2 1991, pages 554-561 When read in combination with any one of the preceding citations	1-28

## INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No.

PCT/SG2004/000425

This Annex lists the known "A" publication level patent family members relating to the patent documents cited in the above-mentioned international search report. The Australian Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

Patent Document Cited in Search Report		Patent Family Member			
EP	1470795	US	2004215335	US	2004254629
US	20040170685	WO	2004075781		
WO	2004000379				
US	20020065546	AU	18524/00	BR	9916636
		EP	1140243	EP	1316323
		NO	20013278	NZ	512307
		WO	0040278	CA	2355873
				HK	1041453
				US	2005021126
WO	2001003607	AU	56390/00	US	6663607
				US	2001047202
WO	1999062432	AU	43320/99	CA	2334223
		US	6605111	US	6666882
		US	2003060782	US	6669721
				ZA	200007149
WO	1999002092	AU	82904/98	CA	2294735
		US	5951599	EP	0994674
Due to data integration issues this family listing may not include 10 digit Australian applications filed since May 2001.					
END OF ANNEX					

**This Page is Inserted by IFW Indexing and Scanning  
Operations and is not part of the Official Record**

**BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ **BLACK BORDERS**
- ☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- ☒ **FADED TEXT OR DRAWING**
- ☐ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- ☐ **SKEWED/SLANTED IMAGES**
- ☐ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- ☐ **GRAY SCALE DOCUMENTS**
- ☐ **LINES OR MARKS ON ORIGINAL DOCUMENT**
- ☐ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- ☐ **OTHER:** \_\_\_\_\_

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.**